BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/21/2019 3:42:23 AM | Browse: 1578 | Download: 2381
Publication Name World Journal of Gastroenterology
Manuscript ID 47141
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Field of Vision
Article Title Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
Manuscript Source Invited Manuscript
All Author List Feng Yang, Chen Jin, De-Liang Fu and Andrew L Warshaw
ORCID
Author(s) ORCID Number
Feng Yang http://orcid.org/0000-0001-8790-6072
Chen Jin http://orcid.org/0000-0002-4330-9716
De-Liang Fu http://orcid.org/0000-0003-4060-8101
Andrew L Warshaw http://orcid.org/0000-0001-7788-3110
Funding Agency and Grant Number
Funding Agency Grant Number
National Key R&D Program of China 2017YFC1308604
Corresponding Author Feng Yang, MD, PhD, Associate Professor, Surgeon, Surgical Oncologist, Department of Pancreatic Surgery, Pancreatic Disease Institute, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Central Urumqi Road, Shanghai 200040, China. yffudan98@126.com
Key Words Pancreatic cancer; Adjuvant therapy; FOLFIRINOX; Neutrophil-to-lymphocyte; Nanoliposomal irinotecan
Core Tip Adjuvant chemotherapy for pancreatic cancer has been developed based on the experiences made with palliative chemotherapy. Nevertheless, the optimal regimen remains controversial. The Partenariat de Recherche en Oncologie Digestive 24 trial showed an impressive benefit of modified FOLFIRINOX over gemcitabine alone. The remarkable results mark a new milestone in treating resectable pancreatic cancer and have now changed the standard of care. Here, we discussed an issue of difference between this trial and previous phase III trials, as well as potential biomarkers predicting therapeutic response. Several ongoing trials of replacing part of the FOLFIRINOX regimen with other drugs for pancreatic cancer were summarized.
Publish Date 2019-06-21 03:42
Citation Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. World J Gastroenterol 2019; 25(23): 2839-2845
URL https://www.wjgnet.com/1007-9327/full/v25/i23/2839.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i23.2839
Full Article (PDF) WJG-25-2839.pdf